Dorsey & Whitney Trust CO LLC Sells 390 Shares of Sanofi (NASDAQ:SNY)

Dorsey & Whitney Trust CO LLC lowered its stake in shares of Sanofi (NASDAQ:SNY) by 1.6% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 24,123 shares of the company’s stock after selling 390 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Sanofi were worth $1,163,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Franklin Resources Inc. raised its position in shares of Sanofi by 13.1% during the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after buying an additional 395,744 shares during the last quarter. Natixis Advisors LLC increased its position in Sanofi by 4.1% in the third quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock worth $165,640,000 after purchasing an additional 114,133 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Sanofi in the fourth quarter worth $135,933,000. JPMorgan Chase & Co. increased its position in Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock worth $133,172,000 after purchasing an additional 399,301 shares during the last quarter. Finally, DAVENPORT & Co LLC increased its position in Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after purchasing an additional 664,455 shares during the last quarter. Institutional investors own 14.04% of the company’s stock.

Wall Street Analyst Weigh In

SNY has been the topic of several research reports. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi presently has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Stock Down 0.3 %

Shares of NASDAQ:SNY opened at $59.25 on Monday. Sanofi has a 52-week low of $45.22 and a 52-week high of $59.72. The stock has a market cap of $150.37 billion, a P/E ratio of 23.80, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The business’s 50 day moving average is $52.65 and its 200 day moving average is $52.73. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sell-side analysts predict that Sanofi will post 4.36 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.